KRAS and osteosarcoma: Based on the present findings, we propose a mechanism by which daraxonrasib suppresses the proliferation and metastatic ability of KRAS mutant osteosarcoma cells by inhibiting overactive AKT/ETS1 signaling (Fig 7).